Mar. 10 at 5:50 PM
$LEXX If Lexaria signed a partnership for its DehydraTECH-CBD hypertension program, the deal would likely resemble a typical early-stage pharma licensing agreement. Because human proof-of-concept data already exists, an upfront payment could fall around
$10M–
$40M. Development milestones tied to Phase 2, Phase 3, and regulatory approval could total
$100M–
$300M, with additional sales milestones potentially adding another
$100M–
$300M. Lexaria would likely earn 5–12% royalties on net sales. Importantly, the pharma partner would typically fund future clinical trials, removing major cost risk. Beyond the economics, even a modest deal would validate DehydraTECH as a drug-delivery platform, potentially opening the door to additional partnerships across other therapeutic areas.
$LLY $PFE $JAZZ
